No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
PD-1 expression	Sarcoma	PD-1 expression	Sarcoma	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3
CD8 positive	Fibrosarcoma	CD8 positive	Fibrosarcoma	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
PD-L1 expression + CTLA4 expression	Lung Cancer	PD-L1 expression + CTLA4 expression	Lung Cancer	GI-101 Sensitive: D – Preclinical GI-101 Sensitive : D	GI-101 Sensitive: D – Preclinical GI-101 Sensitive : D
CD8 positive	Colorectal Cancer	CD8 positive	Colorectal Cancer	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
PD-L1 overexpression	Lung Cancer	PD-L1 overexpression	Lung Cancer	EPIM-001 Sensitive: D – Preclinical EPIM-001 Sensitive : D	EPIM-001 Sensitive: D – Preclinical EPIM-001 Sensitive : D

CD122 agonist

Associations(7)